Screener
Establishment Labs ESTA US — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Establishment Labs in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Establishment Labs’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001688757-26-000050
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | $67,542 | $51,300 | $127,419 | $92,677 |
| Cost of revenue | 19,831 | 16,028 | 37,373 | 29,597 |
| Gross profit | 47,711 | 35,272 | 90,046 | 63,080 |
| Operating expenses: | ||||
| Sales, general and administrative | 46,905 | 44,176 | 90,510 | 83,875 |
| Research and development | 5,096 | 5,203 | 10,337 | 10,258 |
| Total operating expenses | 52,001 | 49,379 | 100,847 | 94,133 |
| Loss from operations | (4,290) | (14,107) | (10,801) | (31,053) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Establishment Labs's US — revenue?
- Establishment Labs (ESTA) reported US — revenue of $24.69M in Q2 2026.
- What does US — revenue mean?
- This metric represents the total gross sales generated from the sale of medical devices and aesthetic products within the United States market. It serves as a key indicator of the company's commercial penetration and adoption rates in the U.S. healthcare sector, reflecting the success of direct sales strategies and regulatory market entry efforts.
Ask your AI about Establishment Labs's us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude